The tally, one vote per house
61 of 70 research houses agree, +4 houses in 30 days. See which houses, free →
The theme holds that strong US corporate earnings growth, including a blended Q3 rate of about 30% by one data provider's count, can keep US stocks rising even though valuations started the year high. Of the 70 houses covering it, 61 argue for the thesis, 5 argue against and 4 are mixed, with 4 more houses added over the last 30 days. Critics counter that the growth is heavily concentrated in a small group of AI-related companies and that elevated valuations have historically meant weaker long-run returns.
Each house counts once: its newest view on the theme in the last 60 days. The counts are computed, not written by AI; the summary is AI-written from the houses’ views, without names.
Who the houses are
- Asset managers24
- Banks23
- Podcasts13
- Independent research firms10
Types only: names are shown to members. See who said what, free →
Houses discussing it, 12 weeks
Houses with a view in the 60 days to each week’s end. Latest: 70 houses on 3 Nov.
What the theme implies
- US equities higher
Positioning
Source: CFTC Commitments of Traders; FinChiefs calculations. Report of 27 Oct 2026. Positioning data →
Named in research
No fund, ETF or index has been named by at least 2 research houses for this theme yet.
Questions
What is the “US earnings” theme?
Strong earnings growth lets US stocks keep rising even though valuations started the year high. It is one of 70 themes FinChiefs counts across published research from banks, asset managers, independent research firms and podcasts.
How many research houses agree?
61 of 70 research houses agree (87%), counting each house's newest view in the last 60 days: 61 agree, 4 are mixed and 5 disagree. That is +4 houses in 30 days. Members see each house by name.
Which instruments do research houses name for this theme?
No fund, ETF or index has been named by at least 2 research houses for this theme yet.
Is this investment advice?
No. Themes summarise what research houses argue. FinChiefs takes no view of its own. Instruments shown are the ones research houses name, not selected or endorsed by FinChiefs. Not investment advice. No prices are shown and no instrument pays to appear.
The Daily Digest in your inbox
Every morning, what published research argued the day before: the cross-asset and macro read in full, then every market in a line.